bbio-10q_20210331.htm
false Q1 0001743881 --12-31 true true P5D P5D P5D P5D P8Y P7Y us-gaap:LicenseMember us-gaap:LicenseMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:OtherNoncurrentAssetsMember us-gaap:OtherNoncurrentAssetsMember 12.0 0.1 P1Y3M 80.0 1.16 84.0 14.3 P6Y3M 95.0 1.53 P5Y1M6D P6Y1M6D P4Y9M18D bbio:OtherAccruedLiabilitiesCurrent1Member us-gaap:OtherNoncurrentLiabilitiesMember P8Y9M18D P8Y2M12D P8Y8M12D P7Y4M24D P7Y10M24D P8Y3M18D P5Y7M6D P7Y9M18D P6Y7D P4M24D P7M24D 0.4761 0.5197 0.0006 0.0013 0001743881 2021-01-01 2021-03-31 xbrli:shares 0001743881 2021-04-30 iso4217:USD 0001743881 2021-03-31 0001743881 2020-12-31 0001743881 bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember 2021-03-31 0001743881 bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember 2021-03-31 0001743881 bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember 2020-12-31 iso4217:USD xbrli:shares 0001743881 2020-01-01 2020-03-31 0001743881 bbio:RedeemableConvertibleNoncontrollingInterestsMember 2020-12-31 0001743881 us-gaap:CommonStockMember 2020-12-31 0001743881 us-gaap:TreasuryStockMember 2020-12-31 0001743881 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001743881 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001743881 us-gaap:RetainedEarningsMember 2020-12-31 0001743881 us-gaap:ParentMember 2020-12-31 0001743881 us-gaap:NoncontrollingInterestMember 2020-12-31 0001743881 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember bbio:AccountingStandardsUpdate202006Member us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001743881 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember bbio:AccountingStandardsUpdate202006Member us-gaap:RetainedEarningsMember 2020-12-31 0001743881 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember bbio:AccountingStandardsUpdate202006Member us-gaap:ParentMember 2020-12-31 0001743881 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember bbio:AccountingStandardsUpdate202006Member 2020-12-31 0001743881 us-gaap:StockCompensationPlanMember us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001743881 us-gaap:StockCompensationPlanMember us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001743881 us-gaap:StockCompensationPlanMember us-gaap:ParentMember 2021-01-01 2021-03-31 0001743881 us-gaap:StockCompensationPlanMember 2021-01-01 2021-03-31 0001743881 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001743881 us-gaap:ParentMember 2021-01-01 2021-03-31 0001743881 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001743881 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0001743881 us-gaap:EmployeeStockMember us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001743881 us-gaap:EmployeeStockMember us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001743881 us-gaap:EmployeeStockMember us-gaap:ParentMember 2021-01-01 2021-03-31 0001743881 us-gaap:EmployeeStockMember 2021-01-01 2021-03-31 0001743881 bbio:SatisfyTaxWithholdingMember us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001743881 bbio:SatisfyTaxWithholdingMember us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001743881 bbio:SatisfyTaxWithholdingMember us-gaap:ParentMember 2021-01-01 2021-03-31 0001743881 bbio:SatisfyTaxWithholdingMember 2021-01-01 2021-03-31 0001743881 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0001743881 bbio:RedeemableConvertibleNoncontrollingInterestsMember 2021-01-01 2021-03-31 0001743881 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001743881 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001743881 bbio:RedeemableConvertibleNoncontrollingInterestsMember 2021-03-31 0001743881 us-gaap:CommonStockMember 2021-03-31 0001743881 us-gaap:TreasuryStockMember 2021-03-31 0001743881 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001743881 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001743881 us-gaap:RetainedEarningsMember 2021-03-31 0001743881 us-gaap:ParentMember 2021-03-31 0001743881 us-gaap:NoncontrollingInterestMember 2021-03-31 0001743881 bbio:RedeemableConvertibleNoncontrollingInterestsMember 2019-12-31 0001743881 us-gaap:CommonStockMember 2019-12-31 0001743881 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001743881 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001743881 us-gaap:RetainedEarningsMember 2019-12-31 0001743881 us-gaap:ParentMember 2019-12-31 0001743881 us-gaap:NoncontrollingInterestMember 2019-12-31 0001743881 2019-12-31 0001743881 us-gaap:StockCompensationPlanMember us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001743881 us-gaap:StockCompensationPlanMember us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001743881 us-gaap:StockCompensationPlanMember us-gaap:ParentMember 2020-01-01 2020-03-31 0001743881 us-gaap:StockCompensationPlanMember 2020-01-01 2020-03-31 0001743881 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001743881 us-gaap:ParentMember 2020-01-01 2020-03-31 0001743881 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001743881 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0001743881 bbio:RedeemableConvertibleNoncontrollingInterestsMember 2020-01-01 2020-03-31 0001743881 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0001743881 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001743881 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001743881 bbio:RedeemableConvertibleNoncontrollingInterestsMember 2020-03-31 0001743881 us-gaap:CommonStockMember 2020-03-31 0001743881 us-gaap:TreasuryStockMember 2020-03-31 0001743881 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001743881 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001743881 us-gaap:RetainedEarningsMember 2020-03-31 0001743881 us-gaap:ParentMember 2020-03-31 0001743881 us-gaap:NoncontrollingInterestMember 2020-03-31 0001743881 2020-03-31 0001743881 bbio:LEOCallOptionMember 2021-01-01 2021-03-31 0001743881 bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember 2021-01-01 2021-03-31 0001743881 bbio:TwoThousandNineteenEmployeeStockPurchasePlanMember 2021-01-01 2021-03-31 xbrli:pure 0001743881 srt:MinimumMember 2021-01-01 2021-03-31 0001743881 bbio:AccountingStandardsUpdate202006Member 2021-03-31 0001743881 bbio:AccountingStandardsUpdate202006Member srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember 2021-01-01 0001743881 bbio:AccountingStandardsUpdate202006Member srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember 2021-01-01 0001743881 bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember 2021-01-01 0001743881 bbio:AccountingStandardsUpdate202006Member srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember 2021-01-01 0001743881 2021-01-01 0001743881 bbio:AccountingStandardsUpdate202006Member srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2021-01-01 0001743881 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-03-31 0001743881 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2021-03-31 0001743881 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-03-31 0001743881 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2021-03-31 0001743881 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-03-31 0001743881 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member 2021-03-31 0001743881 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-03-31 0001743881 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2021-03-31 0001743881 us-gaap:FairValueMeasurementsRecurringMember bbio:SupranationalDebtSecuritiesMember 2021-03-31 0001743881 us-gaap:FairValueMeasurementsRecurringMember bbio:SupranationalDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2021-03-31 0001743881 us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001743881 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2021-03-31 0001743881 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2021-03-31 0001743881 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2021-03-31 0001743881 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-12-31 0001743881 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-12-31 0001743881 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryBillSecuritiesMember 2020-12-31 0001743881 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryBillSecuritiesMember 2020-12-31 0001743881 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2020-12-31 0001743881 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2020-12-31 0001743881 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-12-31 0001743881 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-12-31 0001743881 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001743881 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001743881 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001743881 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001743881 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001743881 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001743881 bbio:MeasurementInputProbabilityOfMilestoneAchievementMember srt:MinimumMember bbio:LEOCallOptionMember 2020-12-31 0001743881 bbio:MeasurementInputProbabilityOfMilestoneAchievementMember srt:MaximumMember bbio:LEOCallOptionMember 2020-12-31 0001743881 us-gaap:MeasurementInputDiscountRateMember srt:MinimumMember bbio:LEOCallOptionMember 2020-12-31 0001743881 us-gaap:MeasurementInputDiscountRateMember srt:MaximumMember bbio:LEOCallOptionMember 2020-12-31 0001743881 srt:MinimumMember bbio:LEOCallOptionMember 2020-01-01 2020-12-31 0001743881 srt:MaximumMember bbio:LEOCallOptionMember 2020-01-01 2020-12-31 0001743881 us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember bbio:LEOCallOptionMember 2020-12-31 0001743881 us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember bbio:LEOCallOptionMember 2020-12-31 0001743881 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember bbio:LEOCallOptionMember 2020-12-31 0001743881 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember bbio:LEOCallOptionMember 2020-12-31 0001743881 bbio:LEOCallOptionMember 2020-12-31 0001743881 us-gaap:MoneyMarketFundsMember 2021-03-31 0001743881 us-gaap:ShortTermInvestmentsMember us-gaap:USTreasurySecuritiesMember 2021-03-31 0001743881 us-gaap:ShortTermInvestmentsMember us-gaap:CommercialPaperMember 2021-03-31 0001743881 us-gaap:ShortTermInvestmentsMember us-gaap:CorporateDebtSecuritiesMember 2021-03-31 0001743881 us-gaap:ShortTermInvestmentsMember bbio:SupranationalDebtSecuritiesMember 2021-03-31 0001743881 us-gaap:ShortTermInvestmentsMember 2021-03-31 0001743881 bbio:LongTermMarketableSecuritiesMember us-gaap:USTreasurySecuritiesMember 2021-03-31 0001743881 bbio:LongTermMarketableSecuritiesMember us-gaap:CorporateDebtSecuritiesMember 2021-03-31 0001743881 bbio:LongTermMarketableSecuritiesMember 2021-03-31 0001743881 us-gaap:MoneyMarketFundsMember 2020-12-31 0001743881 us-gaap:ShortTermInvestmentsMember us-gaap:USTreasuryBillSecuritiesMember 2020-12-31 0001743881 us-gaap:ShortTermInvestmentsMember us-gaap:USTreasurySecuritiesMember 2020-12-31 0001743881 us-gaap:ShortTermInvestmentsMember us-gaap:CommercialPaperMember 2020-12-31 0001743881 us-gaap:ShortTermInvestmentsMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001743881 us-gaap:ShortTermInvestmentsMember 2020-12-31 0001743881 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember bbio:EidosTherapeuticsIncMember 2021-01-01 2021-03-31 0001743881 bbio:EidosTherapeuticsIncMember srt:MaximumMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2019-08-02 2019-08-02 0001743881 bbio:EidosTherapeuticsIncMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2019-08-02 0001743881 bbio:EidosTherapeuticsIncMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2020-02-01 2020-02-29 0001743881 bbio:EidosTherapeuticsIncMember bbio:AgreementAndPlanOfMergerMember 2020-10-05 0001743881 bbio:EidosTherapeuticsIncMember bbio:AgreementAndPlanOfMergerMember srt:MinimumMember 2020-10-05 0001743881 bbio:EidosTherapeuticsIncMember bbio:AgreementAndPlanOfMergerMember srt:MaximumMember 2020-10-05 0001743881 bbio:EidosTherapeuticsIncMember 2021-01-26 2021-01-26 0001743881 bbio:EidosTherapeuticsIncMember 2021-01-26 0001743881 bbio:EidosTherapeuticsIncMember us-gaap:AdditionalPaidInCapitalMember 2021-01-26 2021-01-26 0001743881 bbio:EidosTherapeuticsIncMember us-gaap:AdditionalPaidInCapitalMember 2021-01-26 0001743881 bbio:EidosTherapeuticsIncMember 2020-12-31 0001743881 bbio:BridgeBioPharmaLimitedLiabilityCompanyMember bbio:EntitiesAffiliatedWithPerceptiveLifeSciencesMasterFundLtdMember bbio:LianBioMember 2019-10-31 0001743881 bbio:BridgeBioPharmaLimitedLiabilityCompanyMember bbio:EntitiesAffiliatedWithPerceptiveLifeSciencesMasterFundLtdMember bbio:LianBioMember 2019-12-31 0001743881 bbio:BridgeBioPharmaLimitedLiabilityCompanyMember bbio:EntitiesAffiliatedWithPerceptiveLifeSciencesMasterFundLtdMember bbio:LianBioMember 2021-01-01 2021-03-31 0001743881 bbio:BridgeBioPharmaLimitedLiabilityCompanyMember bbio:EntitiesAffiliatedWithPerceptiveLifeSciencesMasterFundLtdMember bbio:LianBioMember 2020-01-01 2020-03-31 0001743881 bbio:LianBioMember us-gaap:CommonStockMember 2021-03-31 0001743881 bbio:LianBioMember us-gaap:CommonStockMember 2020-12-31 0001743881 bbio:BridgeBioPharmaLimitedLiabilityCompanyMember bbio:EntitiesAffiliatedWithPerceptiveLifeSciencesMasterFundLtdMember bbio:LianBioMember 2019-10-01 2019-10-31 0001743881 bbio:PellePharmIncMember 2021-03-31 0001743881 bbio:PellePharmIncMember 2020-12-31 0001743881 bbio:PellePharmIncMember 2019-03-31 0001743881 bbio:PellePharmIncMember 2021-01-01 2021-03-31 0001743881 bbio:PellePharmIncMember 2020-01-01 2020-03-31 0001743881 bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember 2021-01-01 2021-03-31 0001743881 bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember 2021-01-28 0001743881 bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember 2021-01-28 2021-01-28 0001743881 bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember 2021-01-01 2021-03-31 bbio:TradingDay 0001743881 bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember srt:MaximumMember 2021-01-28 2021-01-28 0001743881 bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember 2020-03-09 0001743881 bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember 2020-03-09 2020-03-09 0001743881 bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember srt:MaximumMember 2020-03-09 2020-03-09 0001743881 bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember 2020-01-01 2020-03-31 0001743881 bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember 2020-03-31 0001743881 bbio:PrincipalValueAndInterestOnTwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember 2021-03-31 0001743881 bbio:InterestAdjustOnTwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember 2021-03-31 0001743881 bbio:PrincipalValueOnTwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNineMember 2021-03-31 0001743881 bbio:PrincipalValueAndInterestOnTwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember 2021-03-31 0001743881 bbio:InterestAdjustOnTwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember 2021-03-31 0001743881 bbio:PrincipalValueOfTwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenMember 2021-03-31 0001743881 bbio:TwoThousandTwentyOneCappedCallTransactionsMember 2021-01-25 2021-01-25 0001743881 bbio:CappedCallTransactionsMember 2020-03-03 2020-03-04 0001743881 bbio:TwoThousandTwentyOneCappedCallTransactionsMember 2021-01-25 0001743881 bbio:CappedCallTransactionsMember 2020-03-04 0001743881 bbio:TwoThousandTwentyOneCappedCallTransactionsMember 2021-01-01 2021-03-31 0001743881 bbio:ShareRepurchaseTransactionsMember bbio:TwoThousandTwentyOneCappedCallTransactionsMember 2021-01-25 2021-01-25 0001743881 bbio:ShareRepurchaseTransactionsMember bbio:CappedCallTransactionsMember 2020-03-03 2020-03-04 0001743881 bbio:ShareRepurchaseTransactionsMember bbio:TwoThousandTwentyOneCappedCallTransactionsMember 2021-01-25 0001743881 bbio:ShareRepurchaseTransactionsMember bbio:CappedCallTransactionsMember 2020-03-04 0001743881 bbio:HerculesCapitalIncMember bbio:DebtInstrumentTrancheOneMember 2018-06-30 0001743881 bbio:HerculesCapitalIncMember bbio:DebtInstrumentTrancheTwoMember 2018-12-31 0001743881 bbio:HerculesCapitalIncMember bbio:DebtInstrumentTrancheThreeMember 2019-05-31 0001743881 us-gaap:PrimeRateMember bbio:HerculesCapitalIncMember bbio:DebtInstrumentTrancheOneMember 2018-06-01 2018-06-30 0001743881 us-gaap:PrimeRateMember bbio:HerculesCapitalIncMember bbio:DebtInstrumentTrancheTwoMember 2018-12-01 2018-12-31 0001743881 us-gaap:PrimeRateMember bbio:HerculesCapitalIncMember bbio:DebtInstrumentTrancheThreeMember 2019-05-01 2019-05-31 0001743881 bbio:HerculesCapitalIncMember bbio:DebtInstrumentTrancheOneMember 2018-06-01 2018-06-30 0001743881 bbio:HerculesCapitalIncMember bbio:DebtInstrumentTrancheTwoMember 2018-12-01 2018-12-31 0001743881 bbio:HerculesCapitalIncMember bbio:DebtInstrumentTrancheThreeMember 2019-05-01 2019-05-31 0001743881 bbio:HerculesCapitalIncMember 2020-04-01 2020-04-30 0001743881 us-gaap:PrimeRateMember bbio:HerculesCapitalIncMember bbio:DebtInstrumentTrancheOneMember 2020-04-01 2020-04-30 0001743881 bbio:HerculesCapitalIncMember bbio:DebtInstrumentTrancheOneMember 2020-04-30 0001743881 bbio:HerculesCapitalIncMember bbio:DebtInstrumentTrancheOneMember 2021-03-31 0001743881 bbio:HerculesCapitalIncMember bbio:DebtInstrumentTrancheOneMember 2020-04-01 2020-04-30 0001743881 us-gaap:PrimeRateMember bbio:HerculesCapitalIncMember bbio:DebtInstrumentTrancheTwoMember 2020-04-01 2020-04-30 0001743881 bbio:HerculesCapitalIncMember bbio:DebtInstrumentTrancheTwoMember 2020-04-30 0001743881 bbio:HerculesCapitalIncMember bbio:DebtInstrumentTrancheTwoMember 2021-03-31 0001743881 bbio:HerculesCapitalIncMember bbio:DebtInstrumentTrancheTwoMember 2020-04-01 2020-04-30 0001743881 us-gaap:PrimeRateMember bbio:HerculesCapitalIncMember bbio:DebtInstrumentTrancheThreeMember 2020-04-01 2020-04-30 0001743881 bbio:HerculesCapitalIncMember bbio:DebtInstrumentTrancheThreeMember 2020-04-30 0001743881 bbio:HerculesCapitalIncMember bbio:DebtInstrumentTrancheThreeMember 2021-03-31 0001743881 bbio:HerculesCapitalIncMember bbio:DebtInstrumentTrancheThreeMember 2020-04-01 2020-04-30 0001743881 bbio:HerculesCapitalIncMember 2020-04-30 0001743881 bbio:HerculesCapitalIncMember 2021-03-31 0001743881 bbio:HerculesCapitalIncMember 2021-01-01 2021-03-31 0001743881 bbio:HerculesCapitalIncMember 2020-01-01 2020-03-31 0001743881 bbio:EidosTherapeuticsIncMember bbio:SiliconValleyBankAndHerculesLoanMember bbio:TrancheALoanMember 2019-11-30 0001743881 bbio:SiliconValleyBankAndHerculesLoanMember bbio:TrancheALoanMember 2019-11-30 0001743881 us-gaap:PrimeRateMember bbio:EidosTherapeuticsIncMember bbio:SiliconValleyBankAndHerculesLoanMember bbio:TrancheALoanMember 2019-11-29 2019-11-30 0001743881 us-gaap:PrimeRateMember bbio:EidosTherapeuticsIncMember bbio:SiliconValleyBankAndHerculesLoanMember bbio:TrancheALoanMember 2021-01-01 2021-03-31 0001743881 bbio:EidosTherapeuticsIncMember bbio:SiliconValleyBankAndHerculesLoanMember bbio:TrancheALoanMember 2019-11-29 2019-11-30 0001743881 srt:MinimumMember bbio:EidosTherapeuticsIncMember bbio:SiliconValleyBankAndHerculesLoanMember bbio:TrancheALoanMember 2019-11-29 2019-11-30 0001743881 srt:MaximumMember bbio:EidosTherapeuticsIncMember bbio:SiliconValleyBankAndHerculesLoanMember bbio:TrancheALoanMember 2019-11-29 2019-11-30 0001743881 bbio:EidosTherapeuticsIncMember bbio:SiliconValleyBankAndHerculesLoanMember 2021-03-31 0001743881 bbio:EidosTherapeuticsIncMember bbio:SiliconValleyBankAndHerculesLoanMember 2021-01-01 2021-03-31 0001743881 bbio:EidosTherapeuticsIncMember bbio:SiliconValleyBankAndHerculesLoanMember 2020-01-01 2020-03-31 0001743881 bbio:LicenseAndCollaborationAgreementMember bbio:QEDTherapeuticsIncMember srt:MaximumMember 2021-03-29 0001743881 bbio:LicenseAndCollaborationAgreementMember bbio:QEDTherapeuticsIncMember 2021-03-29 0001743881 bbio:LicenseAndCollaborationAgreementMember bbio:QEDTherapeuticsIncMember 2021-03-29 2021-03-29 0001743881 bbio:HelsinnTherapeuticsMember bbio:LicenseAndCollaborationAgreementMember 2021-03-29 2021-03-29 0001743881 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001743881 us-gaap:PropertyPlantAndEquipmentMember 2021-01-01 2021-03-31 0001743881 bbio:ManufacturingAgreementMember 2019-12-01 2019-12-31 0001743881 us-gaap:ConstructionInProgressMember 2021-01-01 2021-03-31 0001743881 bbio:AtTheMarketOfferingMember srt:MaximumMember us-gaap:CommonStockMember 2020-07-06 2020-07-07 0001743881 bbio:AtTheMarketOfferingMember srt:MaximumMember us-gaap:CommonStockMember 2020-07-07 0001743881 us-gaap:ResearchAndDevelopmentExpenseMember bbio:BridgeBioServicesIncMember 2021-01-01 2021-03-31 0001743881 us-gaap:ResearchAndDevelopmentExpenseMember bbio:OtherConsolidatedEntitiesMember 2021-01-01 2021-03-31 0001743881 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001743881 us-gaap:GeneralAndAdministrativeExpenseMember bbio:BridgeBioServicesIncMember 2021-01-01 2021-03-31 0001743881 us-gaap:GeneralAndAdministrativeExpenseMember bbio:OtherConsolidatedEntitiesMember 2021-01-01 2021-03-31 0001743881 bbio:BridgeBioServicesIncMember 2021-01-01 2021-03-31 0001743881 bbio:OtherConsolidatedEntitiesMember 2021-01-01 2021-03-31 0001743881 us-gaap:ResearchAndDevelopmentExpenseMember bbio:BridgeBioServicesIncMember 2020-01-01 2020-03-31 0001743881 us-gaap:ResearchAndDevelopmentExpenseMember bbio:EidosTherapeuticsIncMember 2020-01-01 2020-03-31 0001743881 us-gaap:ResearchAndDevelopmentExpenseMember bbio:OtherConsolidatedEntitiesMember 2020-01-01 2020-03-31 0001743881 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001743881 us-gaap:GeneralAndAdministrativeExpenseMember bbio:BridgeBioServicesIncMember 2020-01-01 2020-03-31 0001743881 us-gaap:GeneralAndAdministrativeExpenseMember bbio:EidosTherapeuticsIncMember 2020-01-01 2020-03-31 0001743881 us-gaap:GeneralAndAdministrativeExpenseMember bbio:OtherConsolidatedEntitiesMember 2020-01-01 2020-03-31 0001743881 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001743881 bbio:BridgeBioServicesIncMember 2020-01-01 2020-03-31 0001743881 bbio:EidosTherapeuticsIncMember 2020-01-01 2020-03-31 0001743881 bbio:OtherConsolidatedEntitiesMember 2020-01-01 2020-03-31 0001743881 bbio:TwoThousandNineteenStockOptionAndIncentivePlanMember us-gaap:CommonStockMember 2021-03-31 0001743881 bbio:TwoThousandNineteenInducementEquityPlansMember us-gaap:CommonStockMember 2021-03-31 0001743881 bbio:EidosAwardExchangePlanMember us-gaap:CommonStockMember 2021-03-31 bbio:Grantee 0001743881 bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember bbio:TwoThousandNineteenStockOptionAndIncentivePlanMember 2020-04-22 2020-04-22 0001743881 bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember us-gaap:EmployeeStockOptionMember 2020-04-22 2020-04-22 0001743881 bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember us-gaap:RestrictedStockMember 2020-04-22 2020-04-22 0001743881 bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember bbio:PerformanceBasedRestrictedStockAwardsMember 2020-04-22 2020-04-22 0001743881 bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember 2020-04-22 0001743881 bbio:TwoThousandNineteenStockOptionAndIncentivePlanMember bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember 2020-11-18 2020-11-18 0001743881 us-gaap:EmployeeStockOptionMember bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember 2020-11-18 2020-11-18 0001743881 bbio:PerformanceBasedStockOptionsMember bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember 2020-11-18 2020-11-18 0001743881 bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember 2020-11-18 0001743881 bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember srt:MinimumMember 2020-04-22 2020-04-22 0001743881 bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember srt:MaximumMember 2020-04-22 2020-04-22 0001743881 bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember 2021-01-01 2021-03-31 0001743881 bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember 2020-01-01 2020-12-31 0001743881 bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember us-gaap:RestrictedStockMember 2021-01-01 2021-03-31 0001743881 bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember 2020-12-31 0001743881 bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember 2020-12-31 0001743881 bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember 2021-01-01 2021-03-31 0001743881 bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember bbio:EidosTherapeuticsIncMember 2021-01-01 2021-03-31 0001743881 bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember 2021-01-01 2021-03-31 0001743881 bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember 2021-03-31 0001743881 bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember bbio:EidosTherapeuticsIncMember 2021-03-31 0001743881 bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember 2021-03-31 0001743881 bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember 2020-01-01 2020-12-31 0001743881 bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgramMember 2020-01-01 2020-12-31 0001743881 bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001743881 bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember us-gaap:EmployeeStockOptionMember 2021-03-31 0001743881 bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001743881 bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001743881 bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember us-gaap:RestrictedStockUnitsRSUMember 2021-03-31 0001743881 bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember us-gaap:RestrictedStockMember 2020-12-31 0001743881 bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember us-gaap:RestrictedStockMember 2021-01-01 2021-03-31 0001743881 bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlanMember us-gaap:RestrictedStockMember 2021-03-31 0001743881 us-gaap:EmployeeStockMember 2021-01-01 2021-03-31 0001743881 us-gaap:EmployeeStockMember 2021-03-31 0001743881 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001743881 srt:MinimumMember us-gaap:EmployeeStockMember 2021-01-01 2021-03-31 0001743881 srt:MaximumMember us-gaap:EmployeeStockMember 2021-01-01 2021-03-31 0001743881 bbio:EidosTherapeuticsIncMember bbio:TwoThousandSixteenEquityIncentivePlanAndTwoThousandEighteenStockOptionAndIncentivePlanMember 2021-01-01 2021-03-31 bbio:employee 0001743881 bbio:EidosTherapeuticsIncMember bbio:TwoThousandSixteenEquityIncentivePlanAndTwoThousandEighteenStockOptionAndIncentivePlanMember 2021-03-31 0001743881 us-gaap:OtherLiabilitiesMember 2020-12-31 0001743881 bbio:UnvestedRestrictedStockAwardMember 2021-01-01 2021-03-31 0001743881 bbio:UnvestedRestrictedStockAwardMember 2020-01-01 2020-03-31 0001743881 bbio:UnvestedRestrictedStockUnitMember 2021-01-01 2021-03-31 0001743881 bbio:UnvestedRestrictedStockUnitMember 2020-01-01 2020-03-31 0001743881 bbio:UnvestedMarketBasedRestrictedStockUnitMember 2020-01-01 2020-03-31 0001743881 bbio:UnvestedPerformanceBasedRestrictedStockUnitMember 2021-01-01 2021-03-31 0001743881 bbio:UnvestedPerformanceBasedRestrictedStockUnitMember 2020-01-01 2020-03-31 0001743881 bbio:CommonStockOptionsIssuedAndOutstandingMember 2021-01-01 2021-03-31 0001743881 bbio:CommonStockOptionsIssuedAndOutstandingMember 2020-01-01 2020-03-31 0001743881 bbio:EstimatedSharesIssuablePerformanceBasedMilestoneCompensationArrangementMember 2021-01-01 2021-03-31 0001743881 bbio:EstimatedSharesIssuableEmployeeStockPurchasePlanMember 2021-01-01 2021-03-31 0001743881 bbio:EstimatedSharesIssuableEmployeeStockPurchasePlanMember 2020-01-01 2020-03-31 0001743881 bbio:AssumedConversionOfTwoThousandTwentySevenNotesMember 2021-01-01 2021-03-31 0001743881 bbio:AssumedConversionOfTwoThousandTwentySevenNotesMember 2020-01-01 2020-03-31 0001743881 bbio:AssumedConversionOfTwoThousandTwentyNineNotesMember 2021-01-01 2021-03-31 0001743881 bbio:HerculesCapitalIncMember us-gaap:SubsequentEventMember 2021-04-13 2021-04-13 0001743881 bbio:HerculesCapitalIncMember us-gaap:PrimeRateMember us-gaap:SubsequentEventMember 2021-04-13 2021-04-13 0001743881 bbio:HerculesCapitalIncMember us-gaap:SubsequentEventMember 2021-04-13 0001743881 us-gaap:SubsequentEventMember bbio:TrancheALoanMember bbio:EidosTherapeuticsIncMember bbio:SiliconValleyBankAndHerculesLoanMember 2021-04-13 2021-04-13

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2021

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                 to                

Commission File Number: 001-38959

 

BridgeBio Pharma, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

 

84-1850815

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

421 Kipling Street

Palo Alto, CA

 

94301

(Address of principal executive offices)

 

(Zip Code)

Registrant’s telephone number, including area code: (650) 391-9740

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock

 

BBIO

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

 

Large accelerated filer

 

Accelerated filer

Non-accelerated filer

 

Smaller reporting company

Emerging growth company

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

As of April 30, 2021, the registrant had 149,284,184 shares of common stock, $0.001 par value per share, outstanding.

 

 

 

 


 

 

Table of Contents

 

 

 

 

 

Page

PART I.

 

FINANCIAL INFORMATION

 

 

Item 1.

 

Financial Statements (Unaudited)

 

 

 

 

Condensed Consolidated Balance Sheets

 

3

 

 

Condensed Consolidated Statements of Operations

 

4

 

 

Condensed Consolidated Statements of Comprehensive Loss

 

5

 

 

Condensed Consolidated Statements of Redeemable Convertible Noncontrolling Interests and Stockholders’ Equity (Deficit)

 

6

 

 

Condensed Consolidated Statements of Cash Flows

 

8

 

 

Notes to Condensed Consolidated Financial Statements

 

9

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

33

Item 3.

 

Quantitative and Qualitative Disclosures About Market Risk

 

44

Item 4.

 

Controls and Procedures

 

44

PART II.

 

OTHER INFORMATION

 

 

Item 1.

 

Legal Proceedings

 

45

Item 1A.

 

Risk Factors

 

45

Item 2.

 

Unregistered Sales of Equity Securities and Use of Proceeds

 

45

Item 3.

 

Defaults Upon Senior Securities

 

46

Item 4.

 

Mine Safety Disclosures

 

46

Item 5.

 

Other Information

 

46

Item 6.

 

Exhibits

 

47

Signatures

 

49

 

 

 

 

 

2


 

 

BRIDGEBIO PHARMA, INC.

Condensed Consolidated Balance Sheets

(in thousands, except shares and per share amounts)

 

 

 

March 31,

 

 

December 31,

 

 

 

2021

 

 

2020

 

 

 

(Unaudited)

 

 

(1)

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

471,176

 

 

$

356,082

 

Short-term marketable securities

 

 

447,942

 

 

 

251,011

 

Receivable from a related party

 

 

462

 

 

 

 

Prepaid expenses and other current assets

 

 

25,534

 

 

 

35,731

 

Total current assets

 

 

945,114

 

 

 

642,824

 

Property and equipment, net

 

 

22,816

 

 

 

20,325

 

Operating lease right-of-use assets, net

 

 

12,997

 

 

 

16,508

 

Long-term marketable securities

 

 

82,202

 

 

 

 

Other assets

 

 

30,179

 

 

 

23,931

 

Total assets

 

$

1,093,308

 

 

$

703,588

 

Liabilities, Redeemable Convertible Noncontrolling Interests and Stockholders’ Equity (Deficit)

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

10,340

 

 

$

8,945

 

Accrued compensation and benefits

 

 

20,741

 

 

 

29,682

 

Accrued research and development liabilities

 

 

33,423

 

 

 

27,290

 

Accrued professional services

 

 

4,518

 

 

 

5,579

 

LEO call option liability

 

 

 

 

 

5,550

 

Operating lease liabilities, current portion

 

 

3,807

 

 

 

3,795

 

Term loans, current portion

 

 

3,646

 

 

 

1,458

 

Other accrued liabilities

 

 

18,254

 

 

 

13,349

 

Total current liabilities

 

 

94,729

 

 

 

95,648

 

Term loans, net of current portion

 

 

90,762

 

 

 

92,421

 

2029 Notes, net

 

 

731,747

 

 

 

 

2027 Notes, net

 

 

538,690

 

 

 

383,436

 

Operating lease liabilities, net of current portion

 

 

13,862

 

 

 

14,677

 

Other liabilities

 

 

11,612

 

 

 

9,520

 

Total liabilities

 

 

1,481,402

 

 

 

595,702

 

Commitments and contingencies (Note 8)

 

 

 

 

 

 

 

 

Redeemable convertible noncontrolling interests

 

 

1,271

 

 

 

1,630

 

Stockholders’ equity (deficit):

 

 

 

 

 

 

 

 

Undesignated preferred stock, $0.001 par value; 25,000,000 shares

   authorized; no shares issued and outstanding

 

 

 

 

 

 

Common stock, $0.001 par value; 500,000,000 shares authorized;

   152,289,274 shares issued and 149,114,600 shares outstanding as of

   March 31, 2021, 125,264,070 shares issued and 122,849,389

   shares outstanding as of December 31, 2020

 

 

152

 

 

 

125

 

Treasury stock, at cost; 3,174,674 shares as of March 31, 2021,

   2,414,681 shares as of December 31, 2020

 

 

(125,000

)

 

 

(75,000

)

Additional paid-in capital

 

 

767,117

 

 

 

1,021,344

 

Accumulated other comprehensive income (loss)

 

 

(57

)

 

 

192

 

Accumulated deficit

 

 

(1,037,506

)

 

 

(888,755

)

Total BridgeBio stockholders’ equity (deficit)

 

 

(395,294

)

 

 

57,906

 

Noncontrolling interests

 

 

5,929

 

 

 

48,350

 

Total stockholders’ equity (deficit)

 

 

(389,365

)

 

 

106,256

 

Total liabilities, redeemable convertible noncontrolling interests and

   stockholders’ equity (deficit)

 

$

1,093,308

 

 

$

703,588

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

(1)

The condensed consolidated balance sheet as of December 31, 2020 is derived from the audited consolidated financial statements as of that date.

 

3


 

 

BRIDGEBIO PHARMA, INC.

Condensed Consolidated Statements of Operations

(Unaudited)

(in thousands, except shares and per share amounts)

 

 

 

Three Months Ended March 31,

 

 

 

2021

 

 

2020

 

License revenue

 

$

462

 

 

$

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development

 

 

122,559

 

 

 

68,225

 

General and administrative

 

 

45,407

 

 

 

34,262

 

Total operating expenses

 

 

167,966

 

 

 

102,487

 

Loss from operations

 

 

(167,504

)

 

 

(102,487

)

Other income (expense), net:

 

 

 

 

 

 

 

 

Interest income

 

 

394

 

 

 

1,941

 

Interest expense

 

 

(9,738

)

 

 

(4,010

)

Other income

 

 

5,766

 

 

 

474

 

Total other income (expense), net

 

 

(3,578

)

 

 

(1,595

)

Net loss

 

 

(171,082

)

 

 

(104,082

)

Net loss attributable to redeemable convertible

   noncontrolling interests and noncontrolling

   interests

 

 

8,003

 

 

 

12,232

 

Net loss attributable to common stockholders

   of BridgeBio

 

$

(163,079

)

 

$

(91,850

)

Net loss per share, basic and diluted

 

$

(1.18

)

 

$

(0.78

)

Weighted-average shares used in computing net loss

   per share, basic and diluted

 

 

138,627,729

 

 

 

117,803,438

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 

4


 

 

BRIDGEBIO PHARMA, INC.

Condensed Consolidated Statements of Comprehensive Loss

(Unaudited)

(in thousands)

 

 

 

Three Months Ended March 31,

 

 

 

2021

 

 

2020

 

Net loss

 

$

(171,082

)

 

$

(104,082

)

Other comprehensive income (loss):

 

 

 

 

 

 

 

 

Unrealized gain (loss) on available-for-sale securities

 

 

(249

)

 

 

472

 

Comprehensive loss

 

 

(171,331

)

 

 

(103,610

)

Comprehensive loss attributable to redeemable

  convertible noncontrolling interests and

  noncontrolling interests

 

 

8,003

 

 

 

12,232

 

Comprehensive loss attributable to common stockholders

   of BridgeBio

 

$

(163,328

)

 

$

(91,378

)

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 

5


 

 

BRIDGEBIO PHARMA, INC.

Condensed Consolidated Statements of Redeemable Convertible Noncontrolling Interests and Stockholders’ Equity (Deficit)

(Unaudited)

(in thousands, except shares and per share amounts)

 

 

Three Months Ended March 31, 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

Redeemable

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

BridgeBio

 

 

 

 

 

 

Total

 

 

 

Convertible

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

 

 

Stockholders'

 

 

Noncontrol-

 

 

Stockholders’

 

 

 

Noncontrolling

 

 

 

Common Stock

 

 

Treasury Stock

 

 

Paid-In

 

 

Comprehensive

 

 

Accumulated

 

 

Equity

 

 

ling

 

 

Equity

 

 

 

Interests

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Income

 

 

Deficit

 

 

(Deficit)

 

 

Interests

 

 

(Deficit)

 

Balances as of December 31, 2020 (2)

 

$

1,630

 

 

 

 

122,849,389

 

 

$

125

 

 

 

2,414,681

 

 

$

(75,000

)

 

$

1,021,344

 

 

$

192

 

 

$

(888,755

)

 

$

57,906

 

 

$

48,350

 

 

$

106,256

 

Cumulative effect of ASU 2020-06 adoption

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(168,078

)

 

 

 

 

 

14,328

 

 

 

(153,750

)

 

 

 

 

 

(153,750

)

Issuance of shares under equity

   compensation plans

 

 

 

 

 

 

819,113

 

 

 

1

 

 

 

 

 

 

 

 

 

6,841

 

 

 

 

 

 

 

 

 

6,842

 

 

 

 

 

 

6,842

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

19,841

 

 

 

 

 

 

 

 

 

19,841

 

 

 

 

 

 

19,841

 

Purchase of capped calls

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(61,295

)

 

 

 

 

 

 

 

 

(61,295

)

 

 

 

 

 

(61,295

)

Repurchase of common stock

 

 

 

 

 

 

(759,993

)

 

 

 

 

 

759,993

 

 

 

(50,000

)

 

 

 

 

 

 

 

 

 

 

 

(50,000

)

 

 

 

 

 

(50,000

)

Issuance of common stock under ESPP

 

 

 

 

 

 

65,298

 

 

 

 

 

 

 

 

 

 

 

 

1,651

 

 

 

 

 

 

 

 

 

1,651

 

 

 

 

 

 

1,651

 

Repurchase of common stock to satisfy tax

    withholding

 

 

 

 

 

 

(15,653

)

 

 

 

 

 

 

 

 

 

 

 

(1,021

)

 

 

 

 

 

 

 

 

(1,021

)

 

 

 

 

 

(1,021

)

Repurchase of Eidos noncontrolling interests

   for cash and shares, including transaction

   costs of $70,734

 

 

 

 

 

 

26,156,446

 

 

 

26

 

 

 

 

 

 

 

 

 

(53,856

)

 

 

 

 

 

 

 

 

(53,830

)

 

 

(38,167

)

 

 

(91,997

)

Issuance of noncontrolling interests

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

5,080

 

 

 

5,080

 

Transfers from (to) noncontrolling

    interests

 

 

517

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,690

 

 

 

 

 

 

 

 

 

1,690

 

 

 

(2,207

)

 

 

(517

)

Unrealized loss on available-for-sale

   securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(249

)

 

 

 

 

 

(249

)

 

 

 

 

 

(249

)

Net loss

 

 

(876

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(163,079

)

 

 

(163,079

)

 

 

(7,127

)

 

 

(170,206

)

Balances as of March 31, 2021

 

$

1,271

 

 

 

 

149,114,600

 

 

$

152

 

 

 

3,174,674

 

 

$

(125,000

)

 

$

767,117

 

 

$

(57

)

 

$

(1,037,506

)

 

$

(395,294

)

 

$

5,929

 

 

$

(389,365

)

6


 

 

 

 

 

Three Months Ended March 31, 2020

 

 

 

Redeemable

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

Convertible

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

 

 

BridgeBio

 

 

Noncontrol-

 

 

Total

 

 

 

Noncontrolling

 

 

 

Common Stock

 

 

Treasury Stock

 

 

Paid-In

 

 

Comprehensive

 

 

Accumulated

 

 

Stockholders'

 

 

ling

 

 

Stockholders’

 

 

 

Interests

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Income

 

 

Deficit

 

 

Equity

 

 

Interests

 

 

Equity

 

Balances as of December 31, 2019 (2)

 

$

2,243

 

 

 

 

123,658,287

 

 

$

124

 

 

 

 

 

$

 

 

$

848,107

 

 

$

254

 

 

$

(440,031

)

 

$

408,454

 

 

$

65,279

 

 

$

473,733

 

Issuance of shares under equity

   compensation plans

 

 

 

 

 

 

116,249